Table 1 Characteristics of 103 advanced biliary tract cancer patients treated with gemcitabine and oxaliplatin (GEMOX) with or without erlotinib
Study population | ||
|---|---|---|
GEMOX (n = 54) | GEMOX plus erlotinib (n = 49) | |
Age, years | ||
Median | 62 (45–75) | 59 (39–75) |
Sex | ||
Male | 35 (64.8 %) | 33 (67.3 %) |
Female | 19 (35.2 %) | 16 (32.7 %) |
Primary site | ||
Cholangiocarcinoma | 38 (70.4 %) | 38 (77.6 %) |
Gallbladder (GB) | 16 (29.6 %) | 11 (22.4 %) |
Differentiation | ||
Well/Moderate | 33 (61.1 %) | 26 (53.1 %) |
Poorly | 21 (38.9 %) | 23 (46.9 %) |
Disease status | ||
Recurrent | 4 (7.4 %) | 18 (36.7 %) |
Primarily metastatic | 50 (92.6 %) | 31 (63.3 %) |
Liver only metastasis | ||
Yes | 10 (18.5 %) | 8 (16.3 %) |
No | 44 (81.5 %) | 41 (83.7 %) |
Number of metastatic sites | ||
1 | 43 (79.6 %) | 41 (83.7 %) |
2 ≤ | 11 (20.4 %) | 8 (16.3) |
KRAS status | ||
Mutant | 3 (5.6 %) | 5 (10.2 %) |
Wild | 51 (94.4 %) | 44 (89.8 %) |